Quantcast
Home > Quotes > SNNA

Sienna Biopharmaceuticals, Inc. Common Stock (SNNA) Quote & Summary Data

SNNA 
$16.58
*  
0.38
2.35%
Get SNNA Alerts
*Delayed - data as of Jun. 19, 2018  -  Find a broker to begin trading SNNA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SNNA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
29
Today's High / Low
$ 16.63 / $ 15.89
Share Volume
47,797
50 Day Avg. Daily Volume
86,442
Previous Close
$ 16.20
52 Week High / Low
$ 29.25 / $ 13.37
Market Cap
343,743,175
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -9.03
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.61

Intraday Chart

News for SNNA

Shares Traded

Share Volume:
47,797
50 Day Avg. Daily Volume:
86,442

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -9.03

Trading Range

The current last sale of $16.58 is 24.01% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 16.63 $ 29.25
 Low: $ 15.89 $ 13.37

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Our objective is to develop our multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology patients. We are advancing multiple product candidates derived from our Topical by Design(TM) platform, all of which are designed to be suitable for chronic administration in patients with inflammatory skin diseases and other dermatologic and aesthetic conditions. Our lead candidate from this platform, SNA-120, is a first-in-class inhibitor of Tropomyosin receptor kinase A, or TrkA, in Phase 2b clinical development for the treatment of pruritus, or itch, associated with psoriasis, as well as for psoriasis itself.  ... More ...  

Risk Grade

Where does SNNA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 16.08
Open Date:
Jun. 19, 2018
Close Price:
$ 16.20
Close Date:
Jun. 19, 2018

Consensus Recommendation

Analyst Info